143 related articles for article (PubMed ID: 16978896)
1. Moderate coffee and alcohol consumption improves the estrogen metabolite profile in adjuvant treated breast cancer patients: a pilot study comparing pre- and post-operative levels.
Klug TL; Bågeman E; Ingvar C; Rose C; Jernström H
Mol Genet Metab; 2006 Dec; 89(4):381-9. PubMed ID: 16978896
[TBL] [Abstract][Full Text] [Related]
2. Coffee consumption and CYP1A2*1F genotype modify age at breast cancer diagnosis and estrogen receptor status.
Bågeman E; Ingvar C; Rose C; Jernström H
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):895-901. PubMed ID: 18398030
[TBL] [Abstract][Full Text] [Related]
3. Comparison of plasma and urinary levels of 2-hydroxyestrogen and 16 alpha-hydroxyestrogen metabolites.
Bradlow HL; Jernström H; Sepkovic DW; Klug TL; Narod SA
Mol Genet Metab; 2006 Feb; 87(2):135-46. PubMed ID: 16165383
[TBL] [Abstract][Full Text] [Related]
4. Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status.
Simonsson M; Söderlind V; Henningson M; Hjertberg M; Rose C; Ingvar C; Jernström H
Cancer Causes Control; 2013 May; 24(5):929-40. PubMed ID: 23412805
[TBL] [Abstract][Full Text] [Related]
5. The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers.
Kotsopoulos J; Ghadirian P; El-Sohemy A; Lynch HT; Snyder C; Daly M; Domchek S; Randall S; Karlan B; Zhang P; Zhang S; Sun P; Narod SA
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):912-6. PubMed ID: 17507615
[TBL] [Abstract][Full Text] [Related]
6. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
7. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
[TBL] [Abstract][Full Text] [Related]
8. Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study.
Le Marchand L; Donlon T; Kolonel LN; Henderson BE; Wilkens LR
Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):1998-2003. PubMed ID: 16103451
[TBL] [Abstract][Full Text] [Related]
9. Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women.
Lurie G; Maskarinec G; Kaaks R; Stanczyk FZ; Le Marchand L
Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1521-7. PubMed ID: 15941966
[TBL] [Abstract][Full Text] [Related]
10. Estrogen metabolites and the risk of breast cancer in older women.
Cauley JA; Zmuda JM; Danielson ME; Ljung BM; Bauer DC; Cummings SR; Kuller LH
Epidemiology; 2003 Nov; 14(6):740-4. PubMed ID: 14569192
[TBL] [Abstract][Full Text] [Related]
11. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
12. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
14. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
15. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.
Owusu C; Buist DS; Field TS; Lash TL; Thwin SS; Geiger AM; Quinn VP; Frost F; Prout M; Yood MU; Wei F; Silliman RA
J Clin Oncol; 2008 Feb; 26(4):549-55. PubMed ID: 18071188
[TBL] [Abstract][Full Text] [Related]
16. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
17. Coffee intake and CYP1A2*1F genotype predict breast volume in young women: implications for breast cancer.
Jernström H; Henningson M; Johansson U; Olsson H
Br J Cancer; 2008 Nov; 99(9):1534-8. PubMed ID: 18813311
[TBL] [Abstract][Full Text] [Related]
18. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
19. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
